All In Biotech

Drug Trial Radar · NCT07612280

Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia (ET) and Polycythemia Vera (PV) With Thrombocytosis

Study to Assess Safety and Preliminary Efficacy of Orally Administered JBI-802 in Subjects With Essential Thrombocythemia and Polycythemia Vera With Thrombocytosis

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Oct 21, 2024

Primary completion

Jan 30, 2031

Study completion Jan 30, 2031

Sponsor

Lead sponsor
Jubilant Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2 study is evaluating the safety and preliminary effectiveness of JBI-802, an oral investigational medicine, in adults with essential thrombocythemia (ET) or polycythemia vera (PV) with thrombocytosis (high platelet counts). The study has two parts. Part 1 evaluates different doses to select the recommended Phase 2 dose. The initial dose-escalation portion is complete, and additional participants may receive selected doses to further assess safety and activity. Part 2 will evaluate the selected dose in a larger group of participants with ET or PV. JBI-802 is taken by mouth once daily in 28-day treatment cycles. Participants may continue treatment while they are benefiting, tolerating treatment, and meeting study requirements. Study assessments include medical examinations, laboratory tests, electrocardiograms, symptom assessments, bone marrow evaluations, and imaging when needed.

Conditions

  • Essential Thrombocythemia (ET)
  • Polycythemia Vera

Interventions

  • JBI-802Drug

    CoREST inhibitor dual targeting LSD1 and HDAC6

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation - Incidence of Dose-Limiting Toxicities (DLTs)Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Dose Expansion - Platelet countTime frame: Up to 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Hollywood Private Hospital

    Nedlands, Australia · Recruiting

  • St. Vincent's Hospital Sydney Limited

    Sydney, New South Wales, Australia · Recruiting

  • Macquarie University

    Sydney, New South Wales, Australia · Recruiting

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia · Recruiting

  • St Vincent's Hospital (Melbourne)

    Melbourne, Victoria, Australia · Recruiting

  • Monash Medical Centre

    Melbourne, Victoria, Australia · Recruiting

  • The Perth Blood Institute Limited

    Perth, Western Australia, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.